Treatment of Knee Osteoarthritis with Bone Marrow-Derived Mononuclear Cell Injection: 12-Month Follow-up
| Autor: | Konstantins Kalnberzs, Ilze Enģele, Indrikis Muiznieks, Kristaps Erglis, Eriks Jakobsons, Ieva Briede, Valdis Goncars, Andrejs Erglis, Martins Erglis, Kristaps Blums, Liene Patetko |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
musculoskeletal diseases
Adult Male Pathology medicine.medical_specialty Knee Joint Biomedical Engineering Physical Therapy Sports Therapy and Rehabilitation Articular cartilage Osteoarthritis Peripheral blood mononuclear cell Severity of Illness Index Injections Intra-Articular 03 medical and health sciences 0302 clinical medicine Intra articular Clinical Papers medicine Immunology and Allergy Humans 030203 arthritis & rheumatology business.industry Hematopoietic Stem Cell Transplantation 030229 sport sciences Middle Aged Osteoarthritis Knee medicine.disease Magnetic Resonance Imaging Radiography medicine.anatomical_structure Treatment Outcome Leukocytes Mononuclear Female Bone marrow Stem cell business Month follow up Follow-Up Studies |
| Zdroj: | Cartilage. 10(1) |
| ISSN: | 1947-6043 |
| Popis: | Objectives To evaluate the main symptoms of knee osteoarthritis (OA) and tissue structure changes after a single dose bone marrow–derived mononuclear cell (BM MNC) intra articular injection. Case series study. Patients with knee OA Kellgren Lawrence (K-L) grade II and III received 1 injection of BM MNC. The clinical results were analyzed with the Knee injury and Osteoarthritis Outcome Score (KOOS) and Knee Society Score (KSS) before, 3, 6, and 12 months after injection. Radiological evaluation was performed with a calibrated x-ray and the magnetic resonance (MR) imaging before and 6 to 7 months postinjection. Results A total of 34 knees were treated with BM MNC injections. Mean (±SD) age of patient group was 53.96 ± 14.15 years; there were 16 males, 16 females, KL grade II, 16; KL grade III, 18. The average injected count of BM MNCs was 45.56 ± 34.94 × 106 cells. At the endpoint of 12 months 65% of patients still had minimal perceptible clinical improvement of the KOOS total score. The mean improvement of KOOS total score was +15.3 and of the KSS knee score was +21.45 and the function subscale +27.08 ( P < 0.05) points. The Whole Organ Magnetic Resonance Imaging Score (WORMS) improved from 44.31 to 42.93 points ( P < 0.05). No adverse effects after the BM-MNC injection were observed. Conclusions The single dose BM MNC partially reduces clinical signs of the knee osteoarthritis stage II/III and in some cases, decreases degenerative changes in the joint building tissue over 12-month period. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|